Menarini is the world’s largest Italian biopharmaceutical company, focused on delivering differentiated ethical and consumer healthcare brands across the region. With over 3,300 professionals in 13 major markets, Menarini Asia-Pacific operates across the entire commercial value chain, from regulatory approval and product launch to lifecycle management and offers an unparalleled customer experience to partners wanting to tap into the Asia-Pacific growth story.READ MORE
Singapore, 14 February 2014 – Moberg Pharma AB (OMX: MOB) and Menarini Asia-Pacific, a member of the Menarini Group are pleased to announce that Menarini Asia-Pacific has been granted the exclusive rights to market and sell Kerasal Nail™ in eight Southeast Asian countries.
Oxford BioTherapeutics (OBT) and Berlin-Chemie (Menarini Group) announce today that they have designated a novel enhanced antibody targeting acute myeloid leukemia (AML) as the first clinical development candidate under the companies’ strategic oncology collaboration.
Singapore, 6 November 2013 – Menarini Asia-Pacific, a member of the world’s largest Italian biopharmaceutical company, officially inaugurated the establishment of Menarini (China) Investment Co. Ltd. and the opening of its national headquarters on 29 October 2013 at the Wuhan National Bioindustry Base (“Wuhan Biolake”) in Hubei Province, China.